Current management of the cognitive dysfunction in parkinson's disease: How far have we come?

Experimental Biology and Medicine

Volumn 233, Issue 8, 2008, Pages 941-951

  Vale, Salvador ^a,b  

^a Laboratorios Trinidad   (Mexico)

^b Investigation Unit   (Mexico)

Author keywords

Ampakines; Cholinesterase inhibitors; Cognitive dysfunction; Dopamine; Parkinson's disease; Prefrontal cortex

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMANTADINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CITICOLINE; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FARAMPATOR; GLUTAMATE DECARBOXYLASE; LEVODOPA; MEMANTINE; PALLADIUM; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RILUZOLE; RIVASTIGMINE; ROFECOXIB; ROPINIROLE; SELEGILINE; TACROLIMUS; TOLCAPONE; UBIDECARENONE; UNINDEXED DRUG; ANTIPARKINSON AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

BASAL GANGLION; BRAIN CORTEX; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; CELL THERAPY; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIARRHEA; DOPAMINERGIC ACTIVITY; DRUG TARGETING; EPISODIC MEMORY; FRONTAL LOBE; GENE DELIVERY SYSTEM; GENE THERAPY; HALLUCINATION; HUMAN; HYPOTENSION; HYPOTHESIS; LIVER TOXICITY; MESENCEPHALON; NAUSEA; NEOCORTEX; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PARIETAL LOBE; PARKINSON DISEASE; PREFRONTAL CORTEX; SHORT SURVEY; STEM CELL; TEMPORAL LOBE; TREMOR; VOMITING; WORKING MEMORY; ANIMAL; DRUG ANTAGONISM; ELECTROSTIMULATION THERAPY; PSYCHOLOGICAL ASPECT; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CYCLOOXYGENASE INHIBITORS; DEMENTIA; DOPAMINE AGENTS; ELECTRIC STIMULATION THERAPY; GENE THERAPY; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE; STEM CELL TRANSPLANTATION;

EID: 50649098674     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0707-MR-193     Document Type: Short Survey

References (84)

1. Papapetropoulos S, Ellul J, Polychronopoulos P, Chroni E. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment. Eur J Neurol 11:347-351, 2004.
2. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130:1787-1798, 2007.
3. Hughes TA, Ross HF, Mindham RHS, Spokes EGS. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 110:118-123, 2004.
4. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 57:470-475, 2000.
5. Warren NM, Piggott MA, Perry EK, Burn DJ. Cholinergic systems in progressive supranuclear palsy. Brain 128:239-249, 2005.
6. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78:254-259, 2007.
7. Guo L, Itaya M, Takanashi M, Mizuno Y, Mori H. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 11:305-309, 2005.
8. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405-1410, 2007.
9. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3,4- Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 989:205-213, 2003.
10. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, and Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27:9220-9232, 2007.
11. Bruck A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol, Neurosurg Psychiatry 75:1467-1469, 2004.
12. Cotelli M, Borroni B, Manenti R, Zanetti M, Arevalo A, Cappa SF, Padovani A. Action and object naming in Parkinson's disease without dementia. Eur J Neurol 14:632-637, 2007.
13. Schott BH, Seidenbecher CI, Fenker DB, Lauer CJ, Bunzeck N, Bernstein HG, Tischmeyer W, Gundelfinger ED, Heinze HJ, Duzel E. The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J Neurosci 26:1407-1417, 2006.
14. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32:1011-1020, 2007.
15. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351:2509-2518, 2004.
16. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19:1-8, 2004.
17. Kaufer DI. Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dement Geriatr Cogn Disord 17(Suppl 1): 32-39, 2004.
18. Chen X, Magnotta VA, Duff K, Boles Ponto LL, Schultz SK. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin Neurosci 18:178-185, 2006.
19. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E. Pharmacological aspects of (-)-deprenyl. Curr Med Chem 11:2017-2031, 2004.
20. Tatton WG. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8:S20-S30, 1993.
21. Murphy KJ, Foley AG, O'Connell AW, Regan CM. Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing. Neuro-psychopharmacology 31:90-100, 2006.
22. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra CM, Kolson D, Weihe J, Remmel R, Katzenstein D, Clifford DB; ACTG A5090 Team. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 69:1314-1321, 2007.
23. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653-1661, 2002.
24. Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422-2430, 2005.
25. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 158:1517-1519, 2001.
26. Turle-Lorenzo N, Maurin B, Puma C, Chezaubernard C, Morain P, Baunez C, Nieoullon A, Amalric M. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther 319:914-923, 2006.
27. Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther 305:338-346, 2003.
28. Lokk J. [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure]. Lakartidningen 101:2003-2006, 2004.
29. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 51:1181-1191, 2006.
30. Braz CA, Borges V, Ferraz HB. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 27:25-29, 2004.
31. Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord 21:1380-1383, 2006.
32. Isaacs AM, Senn DB, Yuan M, Shine JP, Yankner BA. Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium. J Biol Chem 281:27916-27923, 2006.
33. Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj 19:471-479, 2005.
34. Inzelberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, Logi C, Rossi C, Klein C, Rabey JM. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 21:1375-1379, 2006.
35. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46: 1551-1556, 1996.
36. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 32:47-55, 1999.
37. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catechol-amines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 97:11869-11874, 2000.
38. Vatassery GT, Bauer T, Dysken M. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr 70:793-801, 1999.
39. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Muller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H; for the German Coenzyme Q10 Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 64:938-944, 2007.
40. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059-1064, 2003.
41. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ 334:987-994, 2007.
42. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 Study Group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30:1204-1215, 2005.
43. Schott BH, Niehaus L, Wittmann BC, Schütze H, Seidenbecher CI, Heinze HJ, Düzel E. Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. Brain 130:2412-2424, 2007.
44. Rowe J, Stephan KE, Friston K, Frackowiak R, Lees A, Passingham R. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain 125:276-289, 2002.
45. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51:156-164, 2002.
46. Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive Tolcapone therapy in early Parkinson's disease patients. J Neurol Neurosurg Psychiatry 78:944-948, 2007.
47. Munirathinam S, Rogers G, Bahr BA. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptors elicits neuroprotection after trimethyltin exposure in hippocampus. Toxicol Appl Pharmacol 185:111-118, 2002.
48. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 8:603-620, 2007.
49. Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 32:1272-1283, 2007.
50. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 43:318-325, 1998.
51. Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 66(Suppl 4):S69-S79, 2006.
52. Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42:261-264, 1997.
53. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550, 2002.
54. Schapira AH. Neuroprotection and dopamine agonists. Neurology 58: S9-S18, 2002.
55. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51-59, 1999.
56. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93-101, 2003.
57. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044-1053, 2004.
58. Aybek S, Gronchi-Perrin A, Berney A, Chiuve SC, Villemure JG, Burkhard PR, Vingerhoets FJ. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord 22:S974-S981, 2007.
59. Contarino MF, Daniele A, Sibilia AH, Romito LM, Bentivoglio AR, Gainotti G, Albanese A. Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 78:248-252, 2007.
60. Geraerts M, Krylyshkina O, Debyser Z, Baekelandt V. Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis. Stem Cells 25:263-270, 2007.
61. Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7:726-735, 2004.
62. Dormady SP, Bashayan O, Dougherty R, Zhang XM, Basch RS. Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment. J Hematother Stem Cell Res 10:125-140, 2001.
63. Munoz-Elias G, Woodbury D, Black IB. Marrow stromal cells, mitosis, and neuronal differentiation: stem cell and precursor functions. Stem Cells 21:437-448, 2003.
64. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplantation 40:609-619, 2007.
65. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27:3328-3337, 2007.
66. Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, Moirano J, Fitzsimons H, Roitberg BZ, Tuccar E, Roberts A, Kaplitt MG, Eidelberg D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27:501-509, 2007.
67. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, Bartus RT. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60:706-715, 2006.
68. Dass B, Olanow CW, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology 66(Suppl 4):S89-S103, 2006.
69. D'Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res 17:281-284, 1995.
70. Barrachina M, Dominguez I, Ambrosio S, Secades J, Lozano R, Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci 215:105-110, 2003.
71. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2:CD000269, 2005.
72. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 27:498-502, 2007.
73. Ganel R, Ho T, Maragakis NJ, Jackson M, Steiner JP, Rothstein JD. Selective up-regulation of the glial Na-+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol Dis 21:556-567, 2006.
74. Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 128:1-6, 2004.
75. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease: an update. Curr Opin Investig Drugs 7:25-32, 2006.
76. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novere N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5:845-854, 2006.
77. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33:1100-1119, 2007.
78. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733, 2007.
79. Pogacić V, Herling P. List of drugs in development for neurodegenerative diseases. Update June 2007. Neurodegener Dis 4:443-486, 2007.
80. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 68:948-952, 2007.
81. Vale S. How migraines impact cognitive function: findings from the Baltimore ECA. Neurology 69:810, 2007.
82. Bak TH, Mioshi E. A cognitive bedside assessment beyond the MMSE: the Addenbrooke's Cognitive Examination. Pract Neurol 7:245-249, 2007.
83. Fellows LK. Advances in understanding ventromedial prefrontal function: the accountant joins the executive. Neurology 68:991-995, 2007.
84. Nadeau SE, Heilman KM. Frontal mysteries revealed. Neurology 68: 1450-1453, 2007.